United States: Practical Implications From Amarin

Amarin is an important US district court opinion affirming the importance of the Second Circuit's Caronia decision and finding that pharmaceutical and medical device companies have a constitutionally protected right to provide truthful and non-misleading information regarding off-label uses of their products.

The US District Court for the Southern District of New York ruled against the Food and Drug Administration (FDA) and upheld the rights of a pharmaceutical manufacturer to make truthful and non-misleading statements regarding off-label uses of its FDA-approved drug, including the right to affirmatively make those statements through sales representatives to healthcare providers, following the US Court of Appeals for the Second Circuit's landmark opinion in United States v. Caronia.1

The court held that plaintiff drug manufacturer Amarin Pharma Inc. (Amarin) may make truthful and non-misleading statements to doctors regarding off-label uses of its FDA-approved drug Vascepa and that such speech may not form the basis of a prosecution for misbranding. Relying heavily on Caronia, US District Judge Paul A. Engelmayer granted Amarin's motion for preliminary relief against the FDA, stating that, without relief, Amarin's "First Amendment rights [would] be chilled by the threat of a misbranding action."2

COURT REJECTS FDA'S READING OF CARONIA

In Amarin, FDA argued strongly for its interpretation of Caronia, asserting that FDA is able to bring a misbranding action against a manufacturer or its representative where the conduct at issue consists solely of truthful and non-misleading speech promoting an off-label use of an approved drug.3 The court squarely rejected that interpretation: "The [c]ourt's considered and firm view is that, under Caronia¸ the FDA may not bring such an action based on truthful promotional speech alone, consistent with the First Amendment."4 FDA also argued that the Caronia decision was limited to the facts of that particular case,5 but the court similarly rejected that argument.6 This important decision further solidifies the free speech protections afforded to drug manufacturers that wish to provide truthful and non-misleading information to doctors about their drugs for off-label uses, particularly in light of contemporary First Amendment law, which has developed and is set forth in Central Hudson Gas and Electric Corp. v. Public Service Communication of New York, 447 U.S. 557 (1980).

AMARIN CITES STUDIES AND THE FDA'S COMPLETE RESPONSE LETTER TO SUPPORT ITS OFF-LABEL USE

Amarin manufactures Vascepa, a pure eicosapentaenoic omega-3 fatty-acid drug currently approved by FDA to reduce triglyceride levels in adult patients with very high triglycerides. Physicians also widely, and lawfully, prescribe Vascepa for patients with "persistently" high triglycerides. To support a requested label change, Amarin conducted a study, called ANCHOR, to evaluate Vascepa for patients with persistently high triglyceride levels who were already on statin therapy.7 The ANCHOR study showed that Vascepa produced a statistically significant decrease in triglyceride levels in persons with persistently high triglycerides. Amarin sought a new indication based on the ANCHOR study results, but in an April 27, 2015 Complete Response Letter, FDA refused approval for the new indication and rejected Amarin's request to incorporate ANCHOR data into Vascepa's labeling. FDA's letter stated that Vascepa "may be considered to be misbranded under the [Federal Food, Drug, and Cosmetic Act (FDCA)] if it is marketed with this change before approval of this supplemental application."8

Amarin sought relief from potential prosecution for use of general and specific statements about the results of the ANCHOR study. After its complaint, Janet Woodcock, director of FDA's Center for Drug and Evaluation and Research, issued a letter setting out FDA's position on Amarin's proposed statements. In that letter, FDA made important concessions about certain communications, noting that many already fell within existing FDA guidance for distribution of reprints. Although the FDA letter sought to moot the dispute altogether, Amarin rejected some of FDA's proposed additional restrictions and conditions. By issuing the letter to the court and noting approaches to make the communications non-misleading (e.g., use of disclaimers), FDA provided industry with a roadmap to construct non-misleading speech. Nevertheless, the court deemed the case ripe because Amarin faced a "non-extinguished threat of a misbranding prosecution."9

COURT TO FDA: YOU'RE CHILLING AMARIN'S RIGHT TO DISCUSS THE TRUTHFUL SCIENCE ON ITS PRODUCT

In opposing Amarin's request for an injunction, FDA raised three primary arguments, all of which were rejected. First, it argued that Amarin's suit was a "frontal assault . . . on the framework for new drug approval that Congress created in 1962." The court dismissed this concern, holding that the FDCA statute from 1962 must be considered in light of more recent First Amendment law that protects truthful and non-misleading commercial speech. Second, the court argued that only certain truthful and not-misleading statements could be protected. The court rejected this argument on the basis that the Caronia holding applied across the board to all truthful and not-misleading speech and that Caronia specifically reached proactive oral statements by a drug manufacturer's sales representatives. Third, FDA argued that it could use truthful and non-misleading statements to establish intent to promote off-label uses. The court declined to consider that argument as "beside the point," writing "Amarin's lawsuit is directed instead to the act requirement—the situation in which a misbranding action takes aim at truthful, non-misleading speech. And Caronia construed the misbranding statute, categorically, not to reach a manufacturer or its representative under those circumstances."10

To be clear, neither Caronia nor Amarin foreclose the potential for prosecutions related to off-label marketing. The court explicitly addressed two important limitations on Caronia that remain unchanged. First, that "the First Amendment does not protect false or misleading commercial speech." And, second, that "the First Amendment protects expression, not conduct." On this second limitation, the court further wrote "[a] manufacturer that engages in non-communicative activities to promote off-label use cannot use the First Amendment as a shield. Caronia holds protected, and outside the reach of the FDCA's misbranding provisions, off-label promotion only where it wholly consists of truthful and non-misleading speech."11

PRACTICAL IMPLICATIONS

Amarin marks an important development post-Caronia and serves as an important affirmation of the right to truthful and non-misleading statements made to promote pharmaceuticals. This decision, if upheld, will cause pharmaceutical and medical device companies to reconsider the scope of promotion distributed for their products. Because the FDA still can take enforcement action against a company for off-label promotion that is inaccurate or misleading, if a company decides to rely on the decision before any potential appeal is resolved, it is critical for the company to ensure that the off-label communications are truthful and non-misleading.

Examples of Protected Activities

  • Sales representatives and others (medical science liaisons, nurse educators, and other field personnel) can initiate discussions and "promote" off-label uses of drugs through truthful and non-misleading statements, which contain adequate disclaimers.
  • Speech covered by this right can be either oral or written and in the form of articles, reprints, guidelines, or other truthful, scientifically accurate, and non-misleading statements.
  • Reprints and other information do not necessarily need to be on a specific product at issue, because the court agreed that articles on the effect of eicosapentaenoic and docosahexaenoic omega-3 fatty acids, the active ingredients in Vascepa, could be distributed.
  • Companies can summarize articles or use other formats as long as the summary is accurate and factual and not misleading (including through material omission).
  • Truthful and non-misleading speech is protected, and the venue is not a decisive factor—however, the government may consider the circumstances surrounding a communication to determine if there is noncommunicative conduct that should be evaluated in considering potential misbranding arguments.
  • Importantly, if the speech is considered promotion and is written, it will need to be submitted to FDA in a signed form 2253 consistent with 21 CFR 314.81(b)(3)(i).
  • As the court noted, companies can seek FDA views on whether the off-label use speech is misleading through FDA's current prelaunch and advisory comments processes; obviously, that will be a strategic decision for each company and may require companies to create decision tree standard operating procedures for when FDA review is requested.

Examples of Activities That Are Outside the Scope of Amarin

  • False or misleading speech that can arise from inaccuracies, inappropriate bias, omissions of material information, dated information, or absence of disclaimers.
  • Knowing and willful noncommunicative activities intended to improperly induce off-label use, such as activities ordinarily subject to the Medicare Anti-Kickback Statute.

Footnotes

[1] Amarin Pharma, Inc. v. United States Food & Drug Administration, et al., No. 1:15-cv-03588 PAE, slip op. at 45 (S.D.N.Y. Aug. 7, 2015).

[2] Id. at 66.

[3] Id. at 18.

[4] Id. at 45.

[5] Id. at 44.

[6] Id. at 48. "This [c]ourt therefore rejects the FDA's reading of Caronia as a mere artifact of that case's particular facts and circumstances." The court further noted, in several places, that the appropriate forum for FDA disagreement with Caronia would have been a petition for rehearing or certiorari, but not this case. See, e.g., p. 50 n. 57.

[7] Id. at 21–23.

[8] Id. at 26.

[9] Id. at 42.

[10] See id. at 49-51.

[11] Id. at 52.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.